Docetaxel

Generic Name: Docetaxel

Brand Names: Taxotere, Docetaxel Accord, Docetaxel Kabi

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₃NO_₁₄

CAS Number: 114977-28-5

Unique Ingredient Identifier: 699121PHCA

Background: Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication: Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer

Associated Therapies: -

Clinical Trials

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Ovarian Cancer
Sarcoma
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 82

Registration Number: NCT00004066

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 3

Completed

Conditions: Adenocarcinoma of the Lung
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Drug: gefitinib
Radiation: radiation therapy
Other: placebo

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 840

Registration Number: NCT00020709

Locations: 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States

S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 33

Registration Number: NCT00014196

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 94 locations

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-15

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 125

Registration Number: NCT00026156

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States

and more 93 locations

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00005627

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020332

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Phase II Bevacizumab + Tax In Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: bevacizumab
Drug: cyclophosphamide
Drug: docetaxel
Drug: doxorubicin hydrochloride
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-17

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 49

Registration Number: NCT00027885

Locations: 🇺🇸
UH-Southwest, Middleburgh Heights, Ohio, United States
🇺🇸
UH-Green Road, South Euclid, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 2 locations

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Biological: trastuzumab
Drug: docetaxel
Drug: vinorelbine

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 76

Registration Number: NCT00041067

Locations: 🇺🇸
Northern Rockies Radiation Oncology Center, Billings, Montana, United States
🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸
Billings Clinic Cancer Center, Billings, Montana, United States

and more 142 locations

Docetaxel in Treating Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel

First Posted Date: 2003-01-27

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00008411

Locations: 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States

R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-07-18

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 35

Registration Number: NCT00028873

Locations: 🇫🇷
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France
🇧🇪
Institut Jules Bordet, Brussels, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy